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Abstract Glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) are a new class of drugs that might have a
potential beneficial effect on bone metabolism. Data on the
effect of GLP-1 RAs and fracture risk are lacking. The aim
of the present study was to investigate the association
between the use of GLP-1 and the risk of fracture. A case–
control study was performed using Danish National Health
Service data. Cases were those who sustained a fracture
and controls were those without a fracture during the study
period (2007–2011), all aged 18 years and above. Condi-
tional logistic regression estimated the odds ratios (OR) of
fracture with current use of DPP4-I use. Analyses were
adjusted for comorbidities and recent drug use. Among
cases (n = 229,114), there were 6993 current non-insulin
anti-diabetic drug (NIAD) users (excluding incretin users)
and 255 GLP-1 RA users. Similarly, among controls
(n = 229,114), 7209 were NIAD users (excluding incretin
users) and 220 were GLP-1 RA users. Current GLP-1 RA
use was not associated with a decreased risk of fracture
[adjusted (adj.) OR 1.16; 95 % CI 0.83–1.63]. Osteoporotic
fracture risk was also not associated with current GLP-1
RA use (adj. OR 0.78; 95 % CI 0.44–1.39). In our nation-
wide case–control study, we identified that the use of GLP-
1 RA was not associated with fracture risk as compared to
the use of other anti-hyperglycemic drugs. Additionally,
current GLP-1 RA use, stratified by cumulative or average
daily dose, is not associated with fracture risk. Further
research should focus on long-term use of GLP-1 RA and
fracture risk.
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Introduction
The risk of fracture is significantly increased in patients
with type 2 diabetes mellitus (T2DM) [1]. It has been
hypothesized that a reduced bone strength or bone quality
plays a role in patients with T2DM [2]. Alternatively, it has
been suggested that anti-hyperglycemic drugs might affect
fracture risk. For instance, observational studies showed
that the use of thiazolidinediones is associated with a
1.3–1.9-fold [3, 4] increased risk of fracture, in particular
in women, as compared to the use of other anti-hyper-
glycemic drugs. Insulin use has been associated with an
elevated fracture risk [5], whereas metformin might be
associated with a reduced fracture risk [6].
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs),
such as exenatide and liraglutide, are a new class of drugs
in the treatment of T2DM. GLP-1 RAs may have a
potential beneficial effect on bone metabolism, established
by binding of GLP-1 RAs to a GLP-1 receptor on osteo-
cytes and osteoblasts, as shown in in vitro studies [7–9].
Consequently, this may result in an increased bone for-
mation and a decreased bone resorption [8, 10]. As a result
of this process, we hypothesize that this then may lead to a
reduced risk of fracture.
However, currently, there are limited data, particularly
epidemiologic, in the literature. A recent meta-analysis of
randomized clinical trials (n = 4255, mean duration of
included studies 67.4 weeks) did not show a reduced risk
of fracture with the use of GLP-1 RAs [11] as compared to
the use of other anti-hyperglycemic drugs. To our knowl-
edge, there is only one observational study examining
fracture risk with GLP-1 RA use which showed no asso-
ciation [12]. In particular, studies with longer durations of
use or stratified to daily dose are required to best under-
stand the association between GLP-1 RA use and fracture
risk. We therefore sought to examine the association
between GLP-1 RA use compared to other anti-hyper-
glycemic drug use and fracture risk in a nation-wide case–
control study.
Methods
Data Source
We utilized data from the Danish National Health Service,
which cover all contacts to the health sector, and include
approximately 5.2 million individuals in 1995 and 5.5
million in 2011 [13]. The unique 10-digit civil registry
number was used to link population-based registries and
generate a complete hospital discharge and prescription
history for each individual [14]. Data on vital status (e.g.,
change of address and date of death) for the entire Danish
population have been collected since 1968 in the Civil
Registration System. All inpatient contacts have been
registered through the Danish National Hospital Discharge
Register [15] since 1977, and outpatient visits to hospitals,
outpatient clinics, and emergency rooms have been inclu-
ded since 1995. In Denmark, prescription records are sent
directly to a Register of Medicinal Product Statistics (i.e., a
prescription database) at the Danish Medicines Agency.
The prescription database includes information on patient’s
civil registry number, the type and amount of drug pre-
scribed according to the Anatomical Therapeutic Chemical
(ATC) classification system, and the date when the pre-
scription was filled. Pharmacy data have been collected
since January 1, 1996. This study was subject to control by
the National Board of Health and the Danish Data Pro-
tection Agency.
Study Design
The study was designed as a case–control study. Cases
were all subjects, both genders and aged 18 years and
above, who sustained a fracture, low or high trauma, (In-
ternational Classification of Diseases and Related Health
Problems (ICD)-10 codes: S02, S12, S22, S32, S42, S52,
S62, S72, S82, S92, T02, T08, T10, and T12) between 9
May 2007 (the first ever prescription of a GLP-1 RA in
Denmark) and 31 December 2011. Controls were all sub-
jects, both genders and aged 18 years and above, who did
not sustain a fracture during the study period. We randomly
selected one control for each case, matched by gender and
year of birth. The controls were selected using incidence
density sampling [16]. The date of the first fracture was
used as the index date for cases, and controls were assigned
the index date of their matched case.
Fractures were classified into the following categories
using ICD-10 codes: hip (S72.0–S72.2), radius/ulna (S52),
and vertebrae (S12, S22.0–S22.1, S32.0–S32.2, S32.7,
S32.8, T08). A major osteoporotic fracture was defined as a
fracture of the hip, radius/ulna, vertebrae, or humerus
(S42.2–S42.4) according to the WHO definition [17].
Exposure of Interest
We identified all drugs bought during the observation
period using the Register of Medicinal Product Statistics.
The dose of the drug was expressed as defined daily dose
(DDD) [18]. ATC code A10B was used to determine
exposure to non-insulin anti-diabetic drugs (NIAD), and
patients were classified as current (1–91 days) or past (over
91 days) NIAD users, based on the time of the most recent
prescription before the index date. Current NIAD users
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were divided into two mutually exclusive categories: never
incretin users and incretin users.
To control for the potential that diabetes might act as a
confounder [2], we employed never incretin use (i.e., cur-
rent NIAD use excluding incretin use) as the reference
category in our analysis. ATC codes A10BX04 and
A10BX07 were used to determine GLP-1 RA exposure
before the index date in the prescription database. Based on
the time since the most recent prescription, cases and
controls were classified as current (1–91 days), recent
(92–182), or past (over 182 days) GLP-1 RA users. The
DDDs estimated the cumulative dose of GLP-1 RAs for
current GLP-1 RA users, expressed as exenatide equiva-
lents. The average daily dose was estimated by dividing the
cumulative exposure by the treatment time (time between
the first GLP-1 RA prescription and the index date).
Potential Confounders
A history of the following potential confounders ever
before the index date were taken into account: chronic
obstructive pulmonary disease (COPD), previous fracture,
rheumatoid arthritis, hypothyroidism, hyperthyroidism,
cancer, retinopathy, alcoholism, secondary osteoporosis
(diabetes type 1, hypogonadism or premature menopause),
and congestive heart failure. The potential confounders
were identified from the National Hospital register using
ICD-10 and ICD-8 codes. Additional potential confounders
included a prescription in the 6 months before the index
date of the following drugs: dipeptidyl peptidase 4 inhibi-
tors (DPP4-Is), oral glucocorticoids [19], lipid-modifying
drugs, antidepressants [20], anxiolytics, hypnotics [21],
antipsychotics, anti-Parkinson drugs [22], antihyperten-
sives [beta-blockers, thiazide diuretics, renin–angiotensin–
aldosterone system (RAAS) inhibitors, calcium channel
blockers, and loop diuretics], and antiarrhythmics. The
prescription database was used to explore the presence of a
prescription of the above-mentioned drugs.
Statistical Analysis
Conditional logistic regression estimated the association
between the use of GLP-1 RAs versus use of other anti-
hyperglycemic drugs and risk of fracture, using the SAS
9.3 software. Analyses were stratified by age, gender, type
of fracture, and for current GLP-1 RA use also by average
daily dose and cumulative exposure. The stratified analyses
were determined a priori, therefore no interaction analyses
was performed. As a sensitivity analysis, we adjusted for
current metformin use, as it has been associated with a
decreased risk of fracture [6]. As a second sensitivity
analyses, we adjusted the final model for insulin use, as
insulin use has been associated with an increased fracture
risk [5]. Final regression models were determined by
stepwise backward elimination using a significance level of
0.05. All results are presented as odds ratios (OR) with the
corresponding 95 % confidence intervals (CI).
Results
Study Population
The study population consisted of 229,145 cases and the
same number of controls. The mean age was 55 years, and
56 % were women. Baseline characteristics are shown in
Table 1.
Among cases, we identified 6993 (3.1 %) current NIAD
users (excluding incretin users) and 255 (0.1 %) GLP-1 RA
users (current, recent, or past). Similarly, we identified
7209 (3.1 %) NIAD users (excluding incretin users), and
220 (0.1 %) GLP-1 RA users among controls. The mean
duration of actual GLP-1 RA use (from first GLP-1 RA
prescription till index date) was 36 weeks.
GLP-1 RA Use and Risk of Any Fracture
Current GLP-1 RA was not associated with a decrease in
fracture risk: adjusted (adj.) OR 1.16, 95 % CI 0.83–1.63.
Similarly, no significant decrease was observed for recent
use (adj. OR 1.03, 95 % CI 0.69–1.53), or for past use (adj.
OR 1.09, 95 % CI 0.82–1.46). Having no prior use of
NIAD (never use) was associated with a significant
increase in risk of fracture (adj. OR 1.10, 95 % CI
1.06–1.14), as well as past NIAD use (adj. OR 1.12, 95 %
CI 1.05–1.20). The risk of fracture was not reduced after
stratification by sex or age (Table 2).
Other Fracture Types
Table 3 shows that current GLP-1 RA use was not asso-
ciated with osteoporotic fracture risk (adj. OR 0.78, 95 %
CI 0.44–1.39). We identified similar trends for recent GLP-
1 RA use (adj. OR 0.97, 95 % CI 0.52–1.79) and for past
use (adj. OR 0.94, 95 % CI 0.60–1.48). Stratification by
sex and age did not substantially change the results (data
not shown). There was no significant association with
fracture risk of the radius/ulna for current GLP-1 RA use
(adj. OR 0.93, 95 % CI 0.48–1.80), recent GLP-1 RA use
(adj. OR 1.32, 95 % CI 0.55–3.17), or for past GLP-1 RA
use (adj. OR 0.93, 95 % CI 0.48–1.80). Stratification by
gender and age did not show a decreased fracture risk (data
not shown). Hip and vertebral fracture risk was not asso-
ciated with GLP-1 RA use (current, recent, or past),
Table 3.
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Table 1 Baseline
characteristics
Characteristic Cases (n = 229,145) Controls (n = 229,145)
Women 127,449 (55.6) 127,449 (55.6)
Mean age at index date (years, SD) 55 (20.6) 55 (20.6)
18–49 years 90,598 (39.5) 90,607 (39.5)
50–59 years 37,247 (16.3) 37,191 (16.2)
60–69 years 38,751 (16.9) 38,805 (16.9)
70–79 years 28,950 (12.6) 28,931 (12.6)
80? years 33,599 (14.7) 33,611 (14.7)
History of comorbidities
Type 1 diabetes 2113 (0.9) 1419 (0.6)
Alcoholism 11,147 (4.9) 4824 (2.1)
Fracture 46,446 (20.2) 15,418 (6.7)
Hyperthyroidism 3715 (1.6) 3688 (1.6)
Hypothyroidism 2887 (1.3) 2496 (1.1)
COPD 10,812 (4.7) 7,418 (3.2)
Congestive heart failure 7141 (3.1) 5424 (2.4)
Cancer 21,893 (9.6) 18,486 (8.1)
Rheumatoid arthritis 3912 (1.7) 2795 (1.2)
Retinopathy 3105 (1.4) 2314 (1.0)
Neuropathy 7915 (3.5) 6093 (2.7)
Secondary osteoporosis 5284 (2.3) 3352 (1.5)
Drug use within 6 months before index date
Anti-hyperglycemic drugs 8541 (3.7) 8676 (3.8)
Biguanides 6223 (2.7) 6678 (2.9)
Sulfonylurea derivatives 3900 (1.7) 3809 (1.7)
Thiazolidinediones 262 (0.1) 183 (0.1)
Glinides 87 (0.0) 83 (0.0)
GLP-1 RAs 255 (0.1) 220 (0.1)
DPP4-Is 643 (0.3) 707 (0.3)
Insulins 4900 (2.1) 3261 (1.4)
Short acting 2046 (0.9) 1139 (0.5)
Intermediate acting 2049 (0.9) 1411 (0.6)
Long acting 1444 (0.6) 869 (0.4)
Combinations 1679 (0.7) 1200 (0.5)
Statins 31,874 (13.9) 32,064 (14.0)
Antiarrhythmics 818 (0.4) 522 (0.2)
Beta-blockers 23,281 (10.2) 23,592 (10.3)
Thiazide diuretics 20,425 (8.9) 21,547 (9.4)
RAAS inhibitors 37,555 (16.4) 39,379 (17.2)
Calcium channel blockers 22,942 (10.0) 22,816 (10.0)
Loop diuretics 16,905 (7.4) 12,766 (5.6)
Antidepressants 33,644 (14.7) 20,338 (8.9)
Anti-Parkinson drugs 3174 (1.4) 1814 (0.8)
Antipsychotics 8032 (3.5) 4867 (2.1)
Anxiolytics 14,668 (6.4) 10,431 (4.6)
Hypnotics 19,137 (8.4) 14,332 (6.3)
Glucocorticoids 9390 (4.1) 6858 (3.0)
Bisphosphonates 7371 (3.2) 4913 (2.1)
Raloxifene 214 (0.1) 148 (0.1)
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Current GLP-1 RA Use Stratified by Cumulative
and Average Daily Dose and Fracture Risk
The risk of any fracture was comparable, and not significantly
reduced, among the cumulative and average daily dose groups,
Table 4. The adjusted OR for the highest cumulative dose
(C5.5 mg exenatide equivalent)was 0.98 (95 %CI 0.50–1.94)
and the adjusted OR for the highest average daily dose
(C22.5 mcg exenatide equivalent per day) was 1.66 (95 % CI
0.86–3.19).Whenonly osteoporotic fractureswere considered,
therewas again no associationwith a decreased risk of fracture.
Adjusted OR for the highest cumulative dose (C5.5 mg
Table 1 continued
Characteristic Cases (n = 229,145) Controls (n = 229,145)
Vitamin D 211 (0.1) 169 (0.1)
Calcium 1885 (0.8) 1375 (0.6)
Strontium ranelate 194 (0.1) 101 (0.0)
PTH 130 (0.1) 70 (0.0)
Calcitonin 2 (0.0) 1 (0.0)
Hormone replacement therapy 11,912 (5.2) 13,955 (6.1)
Beta2-agonists 10,436 (4.6) 8130 (3.6)
Inhaled anticholinergics 4569 (2.0) 3277 (1.4)
Inhaled corticosteroids 5265 (2.3) 4657 (2.0)
Data are number (%) of patients, unless stated otherwise
SD standard deviation, GLP-1 RA glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl peptidase 4
inhibitor, COPD chronic obstructive pulmonary disease, RAAS renin angiotensin aldosterone system, PTH
parathyroid hormone
Table 2 Use of GLP-1 RAs and risk of any fracture
Exposure No. of cases
(N = 229,145)a
No. of controls
(N = 229,145)a
Crude OR
(95 % CI)
Adjusted OR
(95 % CI)b
Never NIAD use 217,623 218,194 1.03 (0.99–1.06) 1.10 (1.06–1.14)*
Past NIAD use 3631 2815 1.33 (1.25–1.41)* 1.12 (1.05–1.20)*
Current NIAD use excluding incretin use 6993 7209 Reference Reference
Past GLP-1 RA use (183–365 days before index date) 120 93 1.33 (1.01–1.74)* 1.09 (0.82–1.46)
Recent GLP-1 RA use (92–182 days before the index date) 55 56 1.01 (0.70–1.47) 1.03 (0.69–1.53)
Current GLP-1 RA use (1–91 days before the index date) 80 71 1.16 (0.84–1.60) 1.16 (0.83–1.63)
By sex
Males 38 39 0.98 (0.63–1.54) 0.97 (0.60–1.57)
Females 42 32 1.37 (0.86–2.18) 1.43 (0.87–2.32)
By age on index date
\50 years 12 10 1.28 (0.52–3.11) 1.19 (0.47–2.98)
50–59 years 20 22 0.95 (0.51–1.75) 0.99 (0.51–1.89)
60–69 years 33 26 1.09 (0.64–1.86) 1.26 (0.71–2.24)
70? years 15 13 1.29 (0.60–2.77) 1.04 (0.46–2.35)
Never NIAD use: no NIAD prescription before the index date
Past NIAD use: most recent NIAD prescription over 91 days before index date
Current NIAD use: most recent NIAD prescription within 91 days before index date
OR odds ratio, CI confidence interval, GLP-1 RA glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl peptidase 4 inhibitor, NIAD non-
insulin anti-diabetic-drugs, COPD chronic obstructive pulmonary disease, RAAS renin–angiotensin–aldosterone system
* Statistically significant, (P\ 0.05)
a The numbers do not add up precisely to the total number of fractures because DPP4-I exposure is not shown
b Adjusted for history of cancer, COPD, fracture, alcoholism, rheumatoid arthritis, secondary osteoporosis, hyperthyroidism, retinopathy,
neuropathy, heart failure and use of DPP4-Is, glucocorticoids, statins, anxiolytics, hypnotics, antidepressants, antipsychotics, anti-Parkinson
drugs, beta-blockers, thiazide diuretics, RAAS inhibitors, loop diuretics, and antiarrhythmics
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exenatide equivalent) was 0.93 (95 % CI 0.30–2.92) and the
adjusted OR for the highest average daily dose (C22 mcg
exenatide equivalent per day) was 1.40 (95 % CI 0.47–4.13).
Sensitivity Analysis
Adjusting the main analysis for current metformin use did
not substantially change our results. The adjusted OR for
current GLP-1 RA use was 1.17 (95 % CI 0.83–1.64), for
recent GLP-1 RA 1.03 (95 % CI 0.70–1.54), and for past
GLP-1 RA use 1.09 (95 % CI 0.82–1.46).
As a second sensitivity analysis, we additionally adjus-
ted the main analysis for insulin use and this did not alter
the results. The adjusted OR for current GLP-1 RA use was
1.13 (0.80–1.58), for recent use 1.00 (0.67–1.49), and for
past use 1.05 (0.79–1.41).
Table 3 Use of GLP-1 RAs and fracture risk at different skeletal sites
Fracture sites No. of casesa No. of controlsa Crude OR (95 % CI) Adjusted OR (95 % CI)
Osteoporotic fracture 96,774 96,774 – –
Never NIAD use 90,297 90,677 1.02 (0.97–1.07) 1.07b (1.02–1.13)*
Current NIAD use excl. incretin use 3957 4058 Reference Reference
Past GLP-1 RA use ([182 days before the index date) 47 41 1.17 (0.77–1.78) 0.94b (0.60–1.48)
Recent GLP-1 RA use (92–182 before the index date) 23 24 0.98 (0.55–1.73) 0.97b (0.52–1.79)
Current GLP-1 RA use (0–91 days before the index date) 23 31 0.76 (0.44–1.30) 0.78b (0.44–1.39)
Hip 24,328 24,328 – –
Never NIAD use 21,923 22,273 0.94 (0.87–1.01) 1.00c (0.92–1.09)
Current NIAD use excl. incretin use 1454 1388 Reference Reference
Past GLP-1 RA use ([182 days before the index date) 9 4 2.11 (0.65–6.86) 1.74c (0.47–6.49)
Recent GLP-1 RA use (92–182 before the index date) 5 4 1.18 (0.32–4.40) 1.34c (0.26–6.93)
Current GLP-1 RA use (0–91 days before the index date) 4 4 0.99 (0.25–3.97) 0.77c (0.16–3.73)
Radius/ulna 47,905 47,905 – –
Never NIAD use 45,848 45,423 1.29 (1.19–1.39)* 1.29d (1.19–1.40)*
Current NIAD use excl. incretin use 1273 1617 Reference Reference
Past GLP-1 RA use ([182 days before the index date) 19 21 1.16 (0.62–2.16) 0.93d (0.48–1.80)
Recent GLP-1 RA use (92–182 before the index date) 11 12 1.18 (0.52–2.68) 1.32d (0.55–3.17)
Current GLP-1 RA use (0–91 days before the index date) 11 20 0.70 (0.34–1.47) 0.93d (0.48–1.80)
Vertebral 9004 9004 – –
Never NIAD use 8396 8450 1.01 (0.87–1.17) 1.11e (0.93–1.32)
Current NIAD use excl. incretin use 364 369 Reference Reference
Past GLP-1 RA use ([182 days before the index date) 4 5 0.80 (0.21–3.02) 0.97e (0.22–4.32)
Recent GLP-1 RA use (92–182 before the index date) 2 4 0.50 (0.09–2.75) 0.30e (0.05–1.84)
Current GLP-1 RA use (0–91 days before the index date) 2 2 1.00 (0.14–7.15) 2.02e (0.28–14.75)
Never NIAD use: no NIAD prescription before the index date
Current NIAD use: most recent NIAD prescription within 91 days before index date
OR odds ratio, CI confidence interval, GLP-1 RA glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl peptidase 4 inhibitor, NIAD non-
insulin anti-diabetic-drugs, COPD chronic obstructive pulmonary disease, RAAS renin–angiotensin–aldosterone system
* Statistically significant, (P\ 0.05)
a The numbers do not add up precisely to the total number of fractures because past NIAD use and DPP4-I exposure are not shown
b Adjusted for (f) and history of retinopathy, heart failure, COPD and use of glucocorticoids, statins, anxiolytics, antipsychotics, beta-blockers,
thiazide diuretics, RAAS inhibitors, and antiarrhythmics
c Adjusted for (f) and history of retinopathy, heart failure, COPD and use of statins, anxiolytics, RAAS inhibitors, antiarrhythmics, gluco-
corticoids, and antipsychotics
d Adjusted for (f) and use of beta-blockers, thiazide diuretics, RAAS inhibitors, and calcium channel inhibitors
e Adjusted for (f) and history of COPD and use of glucocorticoids, anxiolytics, RAAS inhibitors and antipsychotics
f History of cancer, alcoholism, fracture, rheumatoid arthritis and secondary osteoporosis and use of DPP4-Is, antidepressants, anti-Parkinson
drugs, loop diuretics, and hypnotics
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Discussion
The present study showed that current GLP-1 RA use was
not associated with a decreased risk of any fracture, as
compared to the use of other anti-hyperglycemic drugs, and
current GLP-1 RA use was not associated with a reduced
risk of other fracture types. Moreover, stratification of
current GLP-1 RA by cumulative or average daily dose
was not associated with a decreased risk of fracture.
The results of the present study are in line with the
results of a meta-analysis of clinical trials on the effect of
GLP-1 RAs on fracture risk, which showed that fracture
risk was not significantly reduced with use of GLP-1 RA
[11, 23]. Our results are also in keeping with a large
clinical trial (n = 16,492) on the effect of a DPP4-I, sax-
agliptin, which showed no difference in risk of fracture
with the use of DPP4-I use and placebo [24]. Additionally,
the present results are also supported by the results of a
cohort study which was not able to show a decreased risk
of fracture with the use of GLP-RA as compared to the use
of other anti-hyperglycemic drugs [12] and a cohort study
that compared the use of DPP4-I to the use of other anti-
hyperglycemic drugs [25]. The pathway by which DPP4-Is
might affect bone metabolism may be the same as that of
GLP-1 RA because DPP4-Is inhibits the degradation of
GLP-1 [2]. Moreover, our results are indirectly supported
by a clinical trial on the effect of a GLP-1 RA, exenatide,
on markers of bone metabolism [26], which reported that
bone markers were unaffected after 44 weeks of exenatide
treatment.
We acknowledge that our findings are in contrast to
those of a meta-analysis of randomized clinical trials
(n = 22,055) that showed a significant 40 % reduction of
fracture risk with the use of DPP4-Is [27] as compared to
active treatment or placebo. However, studies that were
included in this meta-analysis did not routinely collect
fractures as an outcome of interest, the number of fractures
was low, and different comparator groups had been used
[27]. The results from this meta-analysis should likely be
interpreted with caution as the low number of events in a
meta-analysis of adverse events can give biased estimates
[28, 29].
Results of in vitro studies have suggested that the use of
GLP-1 RAs might have a beneficial effect on bone meta-
bolism [7–9], yet different mechanisms of effect have been
hypothesized. In vitro studies have shown that GLP-1
Table 4 Use of GLP-1 RAs and risk of any fracture stratified by cumulative and average daily dose
Any fracture Osteoporotic fracture
No. of cases
(N = 229,145)a
No. of controls
(N = 229,145)a
Adjusted OR
(95 % CI)b
No. of cases
(N = 96,774)a
No. of controls
(N = 96,774)a
Adjusted OR
(95 % CI)c
Current NIAD use excl. incretins 6993 7209 Reference 3957 4058 Reference
Current GLP-1 RA use 80 71 1.16 (0.83–1.63) 23 31 0.78 (0.44–1.39)
By cumulative exposured
0–1.4 mg 36 34 1.05 (0.63–1.73) 10 17 0.64 (0.28–1.47)
1.4–2.7 mg 14 11 1.60 (0.69–3.69) 3 5 0.57 (0.12–2.74)
2.7–5.5 mg 12 8 1.55 (0.60–3.95) 4 2 2.05 (0.32–13.30)
C5.5 mg 18 18 0.98 (0.50–1.94) 6 7 0.93 (0.30–2.92)
By average daily dosed
\15 mcg/day 16 19 0.91 (0.47–1.84) 3 9 0.35 (0.09–1.39)
15–22.49 mcg/day 38 36 1.07 (0.66–1.73) 12 15 0.78 (0.35–1.75)
C22.5 mcg/day 26 16 1.66 (0.86–3.19) 8 7 1.40 (0.47–4.13)
Recent GLP-1 RA use 55 56 1.03 (0.69–1.53) 23 24 0.97 (0.52–1.79)
Past GLP-1 RA use 120 93 1.09 (0.82–1.46) 47 41 0.94 (0.60–1.48)
OR odds ratio, CI confidence interval, GLP-1 RA glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl peptidase 4 inhibitor, NIAD non-
insulin anti-diabetic-drugs, COPD chronic obstructive pulmonary disease, RAAS renin–angiotensin–aldosterone system
* Statistically significant, (P\ 0.05)
a The numbers do not add up precisely to the total number of fractures because never NIAD, past NIAD and DPP4-I use are not shown
b Adjusted for history of cancer, alcoholism, COPD, fracture, rheumatoid arthritis, hyperthyroidism, secondary osteoporosis, retinopathy,
neuropathy and heart failure and use of DPP4-Is, glucocorticoids, statins, antidepressants, anxiolytics, hypnotics, antipsychotics, anti-Parkinson
drugs, beta-blockers, thiazide diuretics, RAAS inhibitors, loop diuretics, antiarrhythmics
c Adjusted for (a), but not for hyperthyroidism and neuropathy
d In exenatide equivalents
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receptors are present on bone marrow stromal cells [30],
immature osteoblast [31] and osteocytes [10], and binding
of GLP-1 to its receptor on bone cells leads to increased
osteoblast activity [9], and decreased osteoclast activity
[10]. This could then lead to increased bone formation and
a reduced fracture risk. However, more research is needed
to assess whether GLP-1 RAs are also able to bind to GLP-
1 receptors on human bone cells and whether this could
ultimately result in a reduced risk of fracture.
An unexpected finding was that never and past NIAD
use showed an increased fracture risk as compared to the
current use of other anti-hyperglycemic drugs. This may
have been the result of residual confounding by high body
mass index (BMI), which has been shown to decrease
fracture risk [32]. T2DM has been associated with an
increased BMI and therefore it might be that the increased
risk of never NIAD use is a result of a higher BMI in the
current NIAD use group which was used as a reference
group. The past NIAD use group included patients with
T2DM who use insulin only. Insulin use has been associ-
ated with a twofold increased risk of fracture as compared
to patients with T2DM who use NIADs [2].
There are several strengths to the current study. First the
use of a nation-wide population register permitted the
examination of a large number of cases and controls. The
data used were also collected longitudinally, and for pre-
scriptions this permitted us to calculate a reliable cumu-
lative and average daily dose. Second, the data used to
identify fractures have been validated [13]. Third, we were
able to adjust our analyses for many potential confounders.
When interpreting our results, we are mindful of a couple
of limitations. We were not able to adjust for potential
confounders such as BMI, hemoglobin A1c (HbA1c),
smoking, amount of exercise, and serum vitamin D levels.
A high BMI has been associated with a reduced risk of
fracture [2] and therefore a decreased risk of fracture with
GLP-1 RA use could have represented the association
between high BMI and fracture risk. Nevertheless, we did
not show a reduced fracture risk with GLP-1 RA use.
Smoking is a risk factor of fracture [33], but there is no
evidence that GLP-1 RA users have different smoking
behaviors than the patients treated with other anti-hyper-
glycemic drugs. Exercise has been associated with a
decreased risk of fracture [34]; GLP-1 RA users might
perform less exercise which could result in an overesti-
mation of the effect. Lower levels of serum vitamin D have
been associated with more severe T2DM complications
and increased fracture risk [35, 36]. Not adjusting for
serum vitamin D levels might lead to an overestimation of
the effect when GLP-1 RA users have lower serum vitamin
D levels as compared to the users of other anti-hyper-
glycemic drugs. Thus, while we were able to identify a
large number of confounders due to the completeness of
the registry data, it is acknowledged that some residual
confounding might still be present. In addition, we tried to
capture severity of diabetes by correcting our analyses for
known complications of diabetes, such as neuropathy and
retinopathy. Moreover, we used current NIAD use (ex-
cluding incretin use) as a reference group, because diabetes
itself might act as a confounder. Current NIAD use inclu-
ded use of TZDs or insulins, which have been shown to
increase fracture risk [3, 4]. The result of this bias in the
reference category may be an observed artificial inverse
association between GLP-1 RAs use and risk of fracture
which could have falsely supported our hypothesis. How-
ever, we did not observe an inverse association between
GLP-1 RA use and risk of fracture. Current NIAD use also
included metformin use which has been associated with a
reduced fracture risk and therefore it might mask a
decreased association between GLP-1 RA use and fracture
risk. Nevertheless, statistical adjustment of the main anal-
ysis for current metformin use did not alter the results.
Although the total number of fractures was high, the
number of some fracture types (i.e., hip and radius/ulna)
was not high enough to stratify current GLP-1 RA use by
cumulative and average dose, and to keep adequate sta-
tistical power. In the analyses, with hip and vertebral
fracture as outcome, the number of GLP-1 RA users was
quite small, therefore these results should be interpreted
with caution. The average duration of actual GLP-1 RA use
(36 weeks) in the present study was rather short, which
might be the reason that we were unable to observe an
association between GLP-1 RA use and fracture risk.
However, after stratification of current GLP-1 RA use by
cumulative dose, risk of fracture was not decreased in the
group with patients who had used on average 15 micro-
gram exenatide equivalent per day for at least 1 year (cu-
mulative dose: C5.5 mg exenatide equivalent).
In conclusion, we showed in a population-based case–
control study that the use of GLP-1 RAs (current, recent or
past) is not associated with fracture risk as compared to the
use of other anti-hyperglycemic drugs. In addition, current
GLP-1 RA use stratified by cumulative and average daily
dose was not associated with a decreased fracture risk.
More research is needed, and in particular future studies
should focus on the effect of long-term use of GLP-1 RAs
on fracture risk.
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